Ionis Pharmaceuticals Inc.
Congress has disclosed 5 buys and 3 sells of IONS (Ionis Pharmaceuticals Inc.) in official financial disclosures, each linked to its original filing. A transparency record — not investment advice.
Activity Congressional Activity
Fundamentals · FY2026 Valuation
Standard valuation multiples from SEC-reported GAAP financials (trailing twelve months), each compared to the median for —. We use reported GAAP, not forward or adjusted earnings, so our figures can sit higher than sites that do — especially for companies with falling profit. Relative context — not a target price or investment advice.
how it's calculated
8 trades Recent Congressional Trades
Two things to watch per trade: the disclosure lag (how many days passed before the trade was made public) and the price move in that window (how the stock moved during those non-public days). A sell followed by a price drop, or a buy followed by a rise, means well-timed trading — visible here in the open. Note: the Score measures how notable a trade is, not whether it made money — the price move is shown for context and isn't part of it.
| Politician | Chamber | Type | Owner | Date | Disclosure lag | Price move in that window | Amount | Score | Source |
|---|---|---|---|---|---|---|---|---|---|
| Daniel Goldman | House | SELL ◆ insider convergence · moderate | Self · Daniel Goldman Grandchildren 1986 Trust > TACS R3K | 2023-03-06 | 28 days | — | $1K–$15K <0.1% of NW |
75.9 | ↗ filing |
| Donna Shalala | House | SELL | Self | 2019-06-24 | 6 days | — | $1K–$15K | 40.4 | ↗ filing |
| Donna Shalala | House | BUY | Self | 2019-05-08 | 23 days | — | $1K–$15K | 75.9 | ↗ filing |
| Thomas MacArthur | House | BUY | Child | 2016-11-02 | 29 days | — | $1K–$15K | 15.7 | ↗ filing |
| Thomas MacArthur | House | BUY | Joint | 2016-11-02 | 29 days | — | $15K–$50K | 30.7 | ↗ filing |
| Thomas MacArthur | House | BUY | Joint | 2016-02-24 | 6 days | — | $1K–$15K | 22.3 | ↗ filing |
| Thomas MacArthur | House | BUY | Joint | 2016-02-12 | 18 days | — | $1K–$15K | 40.4 | ↗ filing |
| Thomas MacArthur | House | SELL | Joint | 2016-02-02 | 28 days | — | $15K–$50K | 90.9 | ↗ filing |
Corporate insiders · SEC Form 4 Insider Activity
What the company's own officers and directors did in IONS — open-market purchases and sales from SEC Form 4 filings (option exercises, grants and tax withholding are excluded). This is context for the congressional activity above, never a buy/sell signal, and the two datasets are kept separate on purpose. Does convergence mean anything? →
Of the congressional trades in IONS, 1 coincided with corporate insiders moving the same way within 60 days, and 0 with insiders moving the opposite way. This is co-occurrence only — whether it carries any edge is tested honestly on the convergence page.
| Date | Insider | Role | Type | Size | Source |
|---|---|---|---|---|---|
| 2026-10-16 | Swayze Eric | Other | SELL | $2K | ↗ EDGAR |
| 2026-10-16 | Devers Shannon L. | C-suite | SELL | $59K | ↗ EDGAR |
| 2026-07-31 | Hayden Michael R | Director | BUY | $258K | ↗ EDGAR |
| 2026-07-30 | Hayden Michael R | Director | BUY | $801K | ↗ EDGAR |
| 2026-07-07 | Kordasiewicz Holly B. | C-suite | SELL 10b5-1 | $31K | ↗ EDGAR |
| 2026-07-07 | Diaz Allene M. | Director | SELL 10b5-1 | $864K | ↗ EDGAR |
| 2026-07-07 | BENNETT C FRANK | C-suite | SELL 10b5-1 | $463K | ↗ EDGAR |
| 2026-07-07 | BENNETT C FRANK | C-suite | SELL 10b5-1 | $1.3M | ↗ EDGAR |
| 2026-07-01 | KLEIN JOSEPH III | Director | SELL 10b5-1 | $8K | ↗ EDGAR |
| 2026-07-01 | KLEIN JOSEPH III | Director | SELL 10b5-1 | $903K | ↗ EDGAR |
| 2026-06-26 | Monia Brett P | C-suite | SELL 10b5-1 | $4.0M | ↗ EDGAR |
| 2026-06-26 | Schneider Eugene | Other | SELL 10b5-1 | $2.1M | ↗ EDGAR |
| 2026-06-26 | O'NEIL PATRICK R. | Other | SELL 10b5-1 | $246K | ↗ EDGAR |
| 2026-06-26 | Baroldi Joseph | C-suite | SELL 10b5-1 | $452K | ↗ EDGAR |
| 2026-06-25 | Swayze Eric | Other | SELL 10b5-1 | $839K | ↗ EDGAR |
| 2026-06-25 | Monia Brett P | C-suite | SELL 10b5-1 | $1.7M | ↗ EDGAR |
| 2026-06-24 | Monia Brett P | C-suite | SELL 10b5-1 | $1.1M | ↗ EDGAR |
| 2026-06-15 | BERTHELSEN SPENCER R | Director | SELL 10b5-1 | $588K | ↗ EDGAR |
| 2026-06-12 | Kordasiewicz Holly B. | C-suite | SELL 10b5-1 | $3.0M | ↗ EDGAR |
| 2026-06-12 | Kordasiewicz Holly B. | C-suite | SELL 10b5-1 | $1.5M | ↗ EDGAR |
| 2026-06-01 | BERTHELSEN SPENCER R | Director | SELL 10b5-1 | $605K | ↗ EDGAR |
| 2026-05-14 | Monia Brett P | C-suite | SELL 10b5-1 | $253K | ↗ EDGAR |
| 2026-05-13 | Monia Brett P | C-suite | SELL 10b5-1 | $103K | ↗ EDGAR |
| 2026-05-04 | LOSCALZO JOSEPH | Director | SELL 10b5-1 | $4.5M | ↗ EDGAR |
| 2026-05-04 | LOSCALZO JOSEPH | Director | SELL 10b5-1 | $1.3M | ↗ EDGAR |
Combined timeline — Congress & insiders
Both sets of trades on one timeline, newest first, so you can see when they lined up. Congress vs ◆ insider.
| Date | Who | Type | Size | |
|---|---|---|---|---|
| ◆ insider | 2026-10-16 | Swayze Eric Other | SELL | $2K |
| ◆ insider | 2026-10-16 | Devers Shannon L. C-suite | SELL | $59K |
| ◆ insider | 2026-07-31 | Hayden Michael R Director | BUY | $258K |
| ◆ insider | 2026-07-30 | Hayden Michael R Director | BUY | $801K |
| ◆ insider | 2026-07-07 | Kordasiewicz Holly B. C-suite 10b5-1 | SELL | $31K |
| ◆ insider | 2026-07-07 | Diaz Allene M. Director 10b5-1 | SELL | $864K |
| ◆ insider | 2026-07-07 | BENNETT C FRANK C-suite 10b5-1 | SELL | $463K |
| ◆ insider | 2026-07-07 | BENNETT C FRANK C-suite 10b5-1 | SELL | $1.3M |
| ◆ insider | 2026-07-01 | KLEIN JOSEPH III Director 10b5-1 | SELL | $8K |
| ◆ insider | 2026-07-01 | KLEIN JOSEPH III Director 10b5-1 | SELL | $903K |
| ◆ insider | 2026-06-26 | Monia Brett P C-suite 10b5-1 | SELL | $4.0M |
| ◆ insider | 2026-06-26 | Schneider Eugene Other 10b5-1 | SELL | $2.1M |
| ◆ insider | 2026-06-26 | O'NEIL PATRICK R. Other 10b5-1 | SELL | $246K |
| ◆ insider | 2026-06-26 | Baroldi Joseph C-suite 10b5-1 | SELL | $452K |
| ◆ insider | 2026-06-25 | Swayze Eric Other 10b5-1 | SELL | $839K |
| ◆ insider | 2026-06-25 | Monia Brett P C-suite 10b5-1 | SELL | $1.7M |
| ◆ insider | 2026-06-24 | Monia Brett P C-suite 10b5-1 | SELL | $1.1M |
| ◆ insider | 2026-06-15 | BERTHELSEN SPENCER R Director 10b5-1 | SELL | $588K |
| ◆ insider | 2026-06-12 | Kordasiewicz Holly B. C-suite 10b5-1 | SELL | $3.0M |
| ◆ insider | 2026-06-12 | Kordasiewicz Holly B. C-suite 10b5-1 | SELL | $1.5M |
| ◆ insider | 2026-06-01 | BERTHELSEN SPENCER R Director 10b5-1 | SELL | $605K |
| ◆ insider | 2026-05-14 | Monia Brett P C-suite 10b5-1 | SELL | $253K |
| ◆ insider | 2026-05-13 | Monia Brett P C-suite 10b5-1 | SELL | $103K |
| ◆ insider | 2026-05-04 | LOSCALZO JOSEPH Director 10b5-1 | SELL | $4.5M |
FAQ Common questions
How much has Congress traded IONS?
5 disclosed buys and 3 sells of IONS (Ionis Pharmaceuticals Inc.) appear in official congressional financial disclosures.
Is it legal for members of Congress to trade IONS?
Members of Congress may trade stocks but must disclose it under the STOCK Act. QuantCapitol tracks those public disclosures for transparency — nothing here is an accusation of wrongdoing or investment advice.
Where does this data come from?
Official US House Clerk and Senate electronic financial disclosures. Every trade links back to its original filing so you can verify it yourself.